Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
13.91
+0.13 (0.94%)
At close: May 19, 2025, 4:00 PM
14.13
+0.22 (1.58%)
After-hours: May 19, 2025, 6:30 PM EDT
Denali Therapeutics Employees
Denali Therapeutics had 422 employees as of December 31, 2024. The number of employees decreased by 23 or -5.17% compared to the previous year.
Employees
422
Change (1Y)
-23
Growth (1Y)
-5.17%
Revenue / Employee
n/a
Profits / Employee
-$1,075,690
Market Cap
2.02B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
DNLI News
- 13 days ago - Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome - GlobeNewsWire
- 6 weeks ago - Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program - GlobeNewsWire
- 7 weeks ago - Biotech stocks have been hit hard. Why they're a great value now. - Market Watch
- 2 months ago - Denali Therapeutics: Vast Pipeline, First Approval Up Ahead - Seeking Alpha
- 2 months ago - Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - GlobeNewsWire
- 3 months ago - Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa - GlobeNewsWire
- 4 months ago - Why Is Denali Therapeutics Stock Trading Higher On Wednesday? - Benzinga
- 4 months ago - Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains - Seeking Alpha